Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: rodriguez remirez m. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.
Puyalto A, Rodríguez-Remírez M, López I, Iribarren F, Simón JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Solórzano JL, Sandiego S, Peñuelas I, Calvo A, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: rodriguez remirez m. Front Immunol. 2023 Sep 28;14:1272570. doi: 10.3389/fimmu.2023.1272570. eCollection 2023. Front Immunol. 2023. PMID: 37841258 Free PMC article.
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. Macaya I, et al. Among authors: rodriguez remirez m. Nat Commun. 2023 Oct 10;14(1):6332. doi: 10.1038/s41467-023-41828-z. Nat Commun. 2023. PMID: 37816716 Free PMC article.
Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S, Cebrián A, Rodríguez-Remírez M, Mahíllo I, García-García L, Río-Vilariño A, Baños N, de Cárcer G, Monfort-Vengut A, Castellano V, Fernández-Aceñero MJ, García-Foncillas J, Del Puerto-Nevado L. Solanes-Casado S, et al. Among authors: rodriguez remirez m. Biomed Pharmacother. 2021 Dec;144:112347. doi: 10.1016/j.biopha.2021.112347. Epub 2021 Oct 23. Biomed Pharmacother. 2021. PMID: 34700228 Free article.
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Baraibar I, Roman M, Rodríguez-Remírez M, López I, Vilalta A, Guruceaga E, Ecay M, Collantes M, Lozano T, Alignani D, Puyalto A, Oliver A, Ortiz-Espinosa S, Moreno H, Torregrosa M, Rolfo C, Caglevic C, García-Ros D, Villalba-Esparza M, De Andrea C, Vicent S, Pío R, Lasarte JJ, Calvo A, Ajona D, Gil-Bazo I. Baraibar I, et al. Among authors: rodriguez remirez m. Cancers (Basel). 2020 Oct 28;12(11):3169. doi: 10.3390/cancers12113169. Cancers (Basel). 2020. PMID: 33126649 Free PMC article.
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: rodriguez remirez m. Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. Sci Rep. 2019. PMID: 31097738 Free PMC article.
Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study.
Rodríguez-Remírez M, Del Puerto-Nevado L, Fernández Aceñero MJ, Ebrahimi-Nik H, Cruz-Ramos M, García-García L, Solanes S, Baños N, Molina-Roldán E, García-Foncillas J, Cebrián A. Rodríguez-Remírez M, et al. Neuroendocrinology. 2020;110(1-2):50-62. doi: 10.1159/000500591. Epub 2019 Apr 29. Neuroendocrinology. 2020. PMID: 31030198
UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition.
Martinez-Useros J, Garcia-Carbonero N, Li W, Fernandez-Aceñero MJ, Cristobal I, Rincon R, Rodriguez-Remirez M, Borrero-Palacios A, Garcia-Foncillas J. Martinez-Useros J, et al. Among authors: rodriguez remirez m. J Clin Med. 2019 Apr 25;8(4):560. doi: 10.3390/jcm8040560. J Clin Med. 2019. PMID: 31027221 Free PMC article.
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: rodriguez remirez m. Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Sci Rep. 2019. PMID: 30796344 Free PMC article. Clinical Trial.
21 results